Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

January 30, 2016 at 8:40 am

Antimicrobial Agents and Chemotherapy April 2014 V.59 N.4 P.2030-2037

Ralph Corey, Marin H. Kollef, Andrew F. Shorr, Ethan Rubinstein, Martin E. Stryjewski, Alan Hopkins, and Steven L. Barriere

aDepartment of Medicine, Duke Clinical Research Institute, Durham, North Carolina, USA

bPulmonary and Critical Care Division, Washington University School of Medicine, St. Louis, Missouri, USA

cPulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA

dUniversity of Manitoba, Winnipeg, Manitoba, Canada

eDepartment of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina

fTheravance, Inc., South San Francisco, California, USA

U.S. Food and Drug Administration draft guidance for future antibiotic clinical trials of bacterial nosocomial pneumonia recommends the use of diagnostic criteria according to American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines and the use of a primary endpoint of 28-day all-cause mortality.

The effect of applying these guidelines on outcomes of phase III nosocomial pneumonia studies of telavancin was evaluated in a post hoc analysis. ATS/IDSA criteria were applied in a blind fashion to the original all-treated (AT) group. Clinical cure rates at final follow-up were determined in the refined AT and clinically evaluable (CE) groups (ATS/IDSA-AT and ATS/IDSA-CE, respectively).

The exploratory endpoint of 28-day survival was evaluated for the ATS/IDSA-AT group. Noninferiority of telavancin versus vancomycin was demonstrated, with similar cure rates in the ATS/IDSA-AT (59% versus 59%) and ATS/IDSA-CE (83% versus 80%) groups.

Cure rates favored telavancin in ATS/IDSA-CE patients where Staphylococcus aureus was the sole pathogen (86% versus 75%). Overall, 28-day survival rates were similar in the telavancin (76%) and vancomycin (77%) groups but lower in telavancin-treated patients with preexisting moderate-to-severe renal impairment (creatinine clearance [CLCR] of <50 ml/min).

Telavancin should be administered to patients with moderate-to-severe renal impairment only if treatment benefit outweighs the risk or if no suitable alternatives are available.

PDF

http://aac.asm.org/content/58/4/2030.full.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Health Care-Associated Infections, Infecciones nosocomiales, Infecciones respiratorias, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update. Tags: .

Brote de Encefalitis de San Luis en el área metropolitana Buenos Aires Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment


Calendar

January 2016
M T W T F S S
« Dec   Feb »
 123
45678910
11121314151617
18192021222324
25262728293031

Most Recent Posts


%d bloggers like this: